MSD & Co and Moderna have advanced a combination of an mRNA-based cancer vaccine and checkpoint inhibitor Keytruda into a phase 3 trial in skin cancer melanoma, althou
This episode of the pharmaphorum podcast is the first in an occasional series focused on patient engagement that’s being led by Mark Duman, a clinician, consultant and patient advocate.
September is Global Diversity and Inclusion month – David Peacock, managing director of MSD in the UK shares with us his insights on why diversity and inclusion is so important and why it i